Practice improvement in cervical screening and management(PICSM): Symposium on management of cervical abnormalities in adolescents and young women

Journal of Lower Genital Tract Disease

Volumn 14, Issue 1, 2010, Pages 73-80

  Moscicki, Anna Barbara ^a   Cox, J Thomas ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; CANCER CYTODIAGNOSIS; CANCER INCIDENCE; CANCER REGRESSION; CANCER SCREENING; COLPOSCOPY; CONDYLOMA ACUMINATUM; CONFERENCE PAPER; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; RISK FACTOR; SCREENING TEST; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS; WOMEN'S HEALTH;

ADOLESCENT; ADULT; EARLY DETECTION OF CANCER; FEMALE; HEALTH SERVICES ADMINISTRATION; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 76149084819     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3181cec411     Document Type: Conference Paper

References (84)

1. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62. (Pubitemid 35446606)
2. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2005;105: 905-18.
3. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-55. (Pubitemid 47464164)
4. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197: 340-5. (Pubitemid 47464166)
5. Committee on Adolescent Health Care ACOG Committee Opinion No. 436: evaluation and management of abnormal cervical cytology and histology in adolescents. Obstet Gynecol 2009;113:1422-5.
6. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
7. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
8. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197: 279-82.
9. Burchell AN, Winer RL, De Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006;24Suppl 3:S3/52-61.
10. Munoz N, Mendez F, Posso H, Molano M, Van Den Brule AJ, Ronderos M, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.
11. Moscicki AB, Palefsky J, Smith G, Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol 1993;82: 578-85.
12. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade squamous intraepithelial lesions in young women. Lancet 2004;364:1678-83.
13. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural History of cervicovaginal papillomavirus infection in young women. NEJM 1998;338:423-8.
14. Moscicki AB, Ma Y, Farhat S. Repeated detection of HPV 16 in young women. Paper presented at: The 25th International Papillomavirus Conference; May 8-14 2009, 2009; Malmö , Sweden.
15. Boardman LA, Stanko C, Weitzen S, Sung CJ. Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol 2005;105:741-6.
16. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 2007; 197:141.e1-6.
17. Moscicki AB. Personal Communication. 2009.
18. Sasieni P, Castanon A, Parkin MD. Response to: Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3. Int J Cancer 2009 Jul 29. [Epub ahead of print].
19. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent papanicolaou smear diagnoses in Northern New England. Pediatrics 1999;103:539-46.
20. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-7.
21. Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK, et al. Using population-based cancer registry data to assess the burden of human papillomavirusassociated cancers in the United States: overview of methods. Cancer 2008;113(10 Suppl):2841-54.
22. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008;148:493-500.
23. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol 2003;102:765-73.
24. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. Bmj 2009;339:b2968.
25. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8:755-63. (Pubitemid 27404646)
26. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, Mackinnon J, Giuliano A. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:1129-38.
27. Moscicki AB, Grubbs-Burt V, Kanowitz S, Darragh T, Shiboski S. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer 1999;85:1139-44.
28. Moscicki AB, Singer A. The cervical epithelium during puberty and adolescence. In: Jordan JS, A., Shafi M, Jones H III, eds. The Cervix 2nd Edition. Oxford, UK: Blackwell Publishing; 2006.
29. Cox JT. More questions about the accuracy of colposcopy: what does this mean for cervical cancer prevention? Obstet Gynecol 2008;111:1266-7.
30. Chase DM, Kalouyan M, DiSaia PJ. Colposcopy to evaluate abnormal cervical cytology in 2008. Am J Obstet Gynecol 2009;200:472-80.
31. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108:264-72.
32. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathologyreviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127:805-15.
33. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS)Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
34. Ceballos KM, ChapmanW, Daya D, Julian JA, Lytwyn A, McLachlin CM, Elit L. Reproducibility of the histological diagnosis of cervical dysplasia among pathologists from 4 continents. Int J Gynecol Pathol 2008;27:101-7.
35. Horn LC, Reichert A, Oster A, Arndal SF, Trunk MJ, Ridder R, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2008;32:502-12.
36. Park KJ, Soslow RA. Current concepts in cervical pathology. Arch Pathol Lab Med 2009;133:729-38.
37. Samson S-L, Bentley JR, Fahey TJ, McKay DJ, Gil GH. The effect of loop electrosurgical excision. Obstet Gynecol 2005;105:325-32.
38. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291:2100-6.
39. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98.
40. Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE. Pregnancy outcome in women before and after cervical conisation: population based cohort study. Bmj 2008; 337:a1343.
41. Norman JE. Preterm labour. Cervical function and prematurity. Best Pract Res Clin Obstet Gynaecol 2007;21: 791-806.
42. Forss A, Tishelman C, Widmark C, Sachs L. Women's experiences of cervical cellular changes: an unintentional transition from health to liminality? Sociol Health Illn 2004; 26:306-25.
43. Kola S, Walsh JC. Patients' psychological reactions to colposcopy and LLETZ treatment for cervical intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol 2009;146: 96-9.
44. Lerman C, Miller SM, Scarborough R, Hanjani P, Nolte S, Smith D. Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991; 165:658-62.
45. Marteau TM, Walker P, Giles J, Smail M. Anxieties in women undergoing colposcopy. Br J Obstet Gynaecol 1990; 97:859-61.
46. Sorg BA, Whitney P. The effects of trait anxiety and situational stress on working memory capacity. J Research Personality 1992;26:235-41.
47. Idestrom M, Milsom I, Andersson-Ellstrom A. Women's experience of coping with a positive Pap smear: A register-based study of women with two consecutive Pap smears reported as CIN 1. Acta Obstet Gynecol Scand 2003; 82:756-61.
48. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113:18-25.
49. Stier E, Freeman-Wang T, Hochberg L, Hummer A, Venkatraman E, Walker P. Using the cone biopsy to compare colposcopy clinics in New York and London. J Low Genit Tract Dis 2004;8:106-11.
50. Szurkus DC, Harrison TA. Loop excision for highgrade squamous intraepithelial lesion on cytology: correlation with colposcopic and histologic findings. Am J Obstet Gynecol 2003;188:1180-2.
51. Numnum TM, Kirby TO, Leath CA 3rd, Huh WK, Alvarez RD, Straughn JM Jr. A prospective evaluation of ''see and treat'' in women with HSIL Pap smear results: is this an appropriate strategy? J Low Genit Tract Dis 2005;9:2-6.
52. Irvin WP Jr, Andersen WA, Taylor PT Jr, Stoler MH, Rice LW. ''See-and-treat'' loop electrosurgical excision. Has the time come for a reassessment? J Reprod Med 2002;47:569-74.
53. Sasieni P, Castanon A, Parkin DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 2009;124:461-4.
54. FrischM, Biggar RJ, Goedert JJ.Human papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10.
55. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006;24 Suppl 3:S140-6.
56. Moscicki AB, Ellenberg JH, Fahrat S, Xu J. HPV persistence in HIV infected and uninfected adolescent girls: risk factors and differences by phylogenetic types. Journal of Infectious Diseases 2004;190:37-45.
57. Moscicki AB, Ma Y, Holland C, Vermund SH. Cervical ectopy in adolescent girls with and without human immunodeficiency virus infection. J Infect Dis 2001;183:865-70.
58. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4): 1-207; quiz CE201-4.
59. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;196:1447-54.
60. Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008;35:357-60.
61. Hillemanns P, Breugelmans JG, Gieseking F, Benard S, Lamure E, Littlewood KJ, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a crosssectional study. BMC Infect Dis 2008;8:76.
62. Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y, et al. Estimation of the impact of genital warts on healthrelated quality of life. Sex Transm Infect 2008;84:161-6.
63. Scrivener L, Green J, Hetherton J, Brook G. Disclosure of anogenital warts to sexual partners. Sex Transm Infect 2008;84:179-82.
64. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55(RR-11):1-94.
65. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008;111:1371-9.
66. Jones RW, Rowan DM. Spontaneous regression of vulvar intraepithelial neoplasia 2-3. Obstet Gynecol 2000;96: 470-2.
67. Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol 2007;107: 219-22.
68. Centers for Disease Control Primary Care Provider Survey; 2006-2007.
69. Centers for Disease Control. Behavioral Risk Factor Surveillance System. (year)
70. Centers for Disease Control. National Survey of Family Growth; 2002.
71. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. (Pubitemid 46740303)
72. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007;356:1915-27.
73. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
74. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
75. Hildesheim A, Herrero R,Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. Jama 2007;298: 743-53.
76. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
77. MMWR. National immunization survey, 10/10/2008; 2008.
78. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007;111:145-53.
79. Solomon D, Papillo JL, Davey DD. Statement on HPV DNA test utilization. Acta Cytol 2009;53:247-8; discussion 249-52.
80. Solomon D, Breen N, McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007;57:105-11.
81. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. Expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Archives of Medical Research 2009;40:478-85.
82. Goldie S, Kuntz K. A potential error in evaluating cancer screening: a comparison of two approaches for modeling underlying disease progression. Med Decis Making 2003; 23:232-41.
83. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:308-20.
84. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.